Abstract:Background: CLDN encodes a member of the claudin family. Claudin is a tight junction protein that is mainly involved in cell migration. Claudin family is of interest as a potential therapeutic target. Claudin18.2 is one of its important isoforms and is mainly expressed in the stomach. Its expression and prognosis in lung adenocarcinoma remain unknown. The aim of this study was to investigate the correlation between CLDN18 and claudin18.2 expression and prognosis in lung adenocarcinoma. Methods: Two cohorts were introduced in this study: one from The Cancer Genome Atlas (TCGA) CLDN18 mRNA public data (TCGA-LUAD, N = 551); the other from 1079 cases of lung adenocarcinoma diagnosed at the Fourth Hospital of Hebei Medical University, China, with immunohistochemical (IHC) detection of claudin18.2 in tissue microarrays. the IHC-positive cases were again verified by fluorescence in situ hybridization (FISH). Results: The mRNA expression of CLDN18 was significantly lower in lung adenocarcinoma tissues than in normal lung tissues (P < 0.05). Among 1079 Chinese lung adenocarcinoma cases, the overall positive rate of IHC for Claudin18.2 was 7.78% (84/1079). Among those positive for IHC, the positive rate of FISH was 11.9% (10/84), which accounted for 0.9% of the total number of cases (10/1079). To explore the best scoring scheme for Claudin 18.2, we used a four-group (IHC4) and two-group (IHC2) scoring method for evaluation. We found that IHC4 better explained Claudin 18.2 expression and helped us to find specific differences in clinical factors for weak, moderate and strong Claudin 18.2 expression. This difference was not discernible in the IHC2 score. By survival analysis, we found that Claudin 18.2 (IHC4) was able to stratify the prognosis of lung adenocarcinoma patients, with strongly positive patients having a better prognosis than the other subgroups (p < 0.05). We also found that patients with EGFR wild type or PD-L1 < 1% accompanied by strong positive claudin18.2 had a significantly better prognosis than other subgroups (P < 0.05). Conclusion: Claudin18.2 (IHC4) better reveals the clinical and prognostic characteristics of patients with lung adenocarcinoma. Patients with EGFR wild type and PD-L1 < 1% have a better prognosis and partially overlap with claudin18.2 expression, so claudin18.2 may also be an important biomarker for lung adenocarcinoma testing, which is particularly important for EGFR wild type and PD-L1 < 1%.

Cytokeratin 18 Knockdown Decreases Cell Migration and Increases Chemosensitivity in Non-Small Cell Lung Cancer.

[Effect of RAD18-siRNA on Proliferation and Chemotherapy Sensitivity of Human Esophageal Squamous Cell Carcinoma ECA-109 Cells].

EGR1 Decreases the Malignancy of Human Non-Small Cell Lung Carcinoma by Regulating KRT18 Expression.

The serum level of CC chemokine ligand 18 correlates with the prognosis of non-small cell lung cancer

Cc Chemokine Ligand 18(ccl18) Promotes Migration and Invasion of Lung Cancer Cells by Binding to Nir1 Through Nir1-Elmo1/Doc180 Signaling Pathway

Expression Analysis Of Cdc42 In Lung Cancer And Modulation Of Its Expression By Curcumin In Lung Cancer Cell Lines

FGF18 Inhibits Clear Cell Renal Cell Carcinoma Proliferation and Invasion Via Regulating Epithelial-Mesenchymal Transition.

CCL18 Promotes the Metastasis of Squamous Cell Carcinoma of the Head and Neck Through MTDH‐NF‐κB Signalling Pathway

Fibroblast Growth Factor 18 Promotes Proliferation and Migration of H460 Cells Via the ERK and P38 Signaling Pathways.

CXCL5 Regulation of Proliferation and Migration in Human Non-Small Cell Lung Cancer Cells

Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma

Antitumor Efficacy of CC Motif Chemokine Ligand 19 in Colorectal Cancer

KRT18 Modulates Alternative Splicing of Genes Involved in Proliferation and Apoptosis Processes in Both Gastric Cancer Cells and Clinical Samples

[Immunotechnology and production of biological materials laboratory].

Fgf18 Enhances Migration And The Epithelial-Mesenchymal Transition In Breast Cancer By Regulating Akt/Gsk3 Beta/B-Catenin Signaling

Claudin-3 Inhibits Lung Squamous Cell Carcinoma Cell Epithelial-mesenchymal Transition and Invasion Via Suppression of the Wnt/β-catenin Signaling Pathway.

Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha(9)beta(1).

Ccr1 Knockdown Suppresses Human Non-Small Cell Lung Cancer Cell Invasion

SPN-model based simulation of a wearable health monitoring system

MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma

Keratin 17 Promotes Lung Adenocarcinoma Progression by Enhancing Cell Proliferation and Invasion